ALKEM2024-04-012024-06-30 ALKEM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member ALKEM2024-06-30 ALKEM2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-09 2024-07-25 INR Millions First quarter 11:00:00 13:00:00 2024-08-09 2024-08-09 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2024-04-01 2024-06-30 Unaudited Consolidated 30318200000.00 1203100000.00 31521300000.00 8371600000.00 3826600000.00 -1438700000.00 6022700000.00 291100000.00 804800000.00 7449600000.00 25327700000.00 6193600000.00 0.00 6193600000.00 1244300000.00 -553100000.00 691200000.00 0.00 5502400000.00 0.00 0.00 0.00 0.00 5502400000.00 41100000.00 5543500000.00 5451600000.00 50800000.00 5495700000.00 47800000.00 239100000.00 2 45.60 45.60 0.00 0.00 45.60 45.60 1.The above unaudited consolidated financial results are prepared in accordance wilh the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2. The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 08 August 2024 and subsequently approved by the Board of Directors at its meeting held on 09 August 2024. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2024. The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to 31 December 2023, which were subjected to limited review. 3a. Consequent to changes in market dynamics and assessment of recoverable value where indicators of impairment were identified, the group has recognized an impairment loss of: - Rs. 415.6 Million in respect of its plant located at Indore during the previous quarter and year ended 31 March 2024 - Rs. 576.6 Million in respect to the plant located at St. Louis, USA, a unit under S&B Pharma LLC, a subsidiary of the Company in the previous year ended 31 March 2024. These amounts are reflected under 'Exceptional Items' in the respective periods. 3b. During the year ended 31 March 2024, a Cyber security incident which compromised business email IDs of certain employees at one of the Group’s subsidiaries, resulted in a fraudulent transfer of Rs. 513.1 Million of which the Group has recovered an amount of Rs. 290.4 Million in quarter ended 31 March 2024 resulting in a net amount of Rs. 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024. 4. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Other Expenses 7449600000.00 Remeasurements of defined benefit plans -49800000.00 -49800000.00 -16000000.00 Foreign currency translation difference of foreign operations 74900000.00 74900000.00 0.00